SAR228810

SAR228810 is a humanized IgG4 monoclonal antibody inhibitor targeting amyloid β (Aβ) with a KD of 0.43 nM for protofibrillar Aβ over monomeric Aβ. SAR228810 significantly inhibits the brain amyloid plaque formation and oligomer-induced synaptic dysfunction and neurite loss. SAR228810 has significant protection against Aβ-mediated neuritotoxicity. MINT1526A can be used for Alzheimer’s disease imaging and immunotherapy research[1][2].

12352100

Amyloid-β

Neuronal Signaling

Neurological Disease

[1]Wang Z, et al. Learnings about Aβ from human brain recommend the use of a live-neuron bioassay for the discovery of next generation Alzheimer's disease immunotherapeutics. Acta Neuropathol Commun. 2023 Mar 10;11 (1) :39. |[2]Pradier L, et al. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA) . Alzheimers Res Ther. 2018 Nov 28;10 (1) :117.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P991654/

Inhibitory Antibodies

No Development Reported